Number and percentage (95% CI) of indeterminate results, number of positive and interpretable results and positive sensitivity rates (percentage; 95% CI) of QuantiFERON® Gold in Tube (QFT-GIT) in pulmonary TB patients stratified by HIV status and disease localization.

Footnotes: QFT-GIT: QuantiFERON® Gold in Tube; HIV: human immunodeficiency virus; TB: tuberculosis.
(a)QFT-GIT with specific antigen cut –off point: 0.35 IU/mL.
(b)QFT-GIT with PHA cut –off point: 0.50 IU/mL.
(c)Clinical sensitivity: overall sensitivity calculated on the total of patients tested (indeterminate results included as negative).
(d)Laboratory sensitivity: sensitivity calculated only on the interpretable results (indeterminate results excluded).